Drug Treatment

  • Brian V. Reamy
  • Brian K. Unwin

General Principles of Drug Treatment of Hyperlipidemia

Many patients require pharmacologic therapy to reach their lipid goals in addition to the therapeutic lifestyle interventions of diet, therapeutic foods, and exercise discussed in previous chapters. The following five key principles should guide drug selection:
  1. 1.

    Be sure the intensity of therapy is guided by an accurate coronary risk assessment of the patient.

  2. 2.

    Maximize monotherapy before starting combination drug therapy.

  3. 3.

    Prescribe a dosage of a statin designed to reach your target LDL level as your initial dose as opposed to dosage titration.

  4. 4.

    Select medicines appropriate for any patient comorbidity.

  5. 5.

    Individualize your therapeutic plan for each patient by remaining cognizant of unique issues that special populations may present (see Chapter 7).


Each of these five key principles is now be reviewed in detail.

Base Intensity of Drug Therapy on an Accurate Risk Assessment

Intensity of therapy should be guided by...


High Density Lipoprotein Irritable Bowel Syndrome Grapefruit Juice Creatinine Kinase Bile Acid Sequestrant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Choice of lipid regulating drugs. Med Lett 2001;43:43–48.Google Scholar
  2. 2.
    Three new drugs for hyperlipidemia. Med Lett 2003;45:17–19.Google Scholar
  3. 3.
    McKenney JM, Proctor JD, Harris S, et al. A comparison of the efficacy and toxic effects of sustained release vs. immediate release niacin in hypercholesterolemic patients. JAMA 1994;271:672–677.PubMedCrossRefGoogle Scholar
  4. 4.
    Staffa JA, Cahng J, Green L. Cerivistatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539–540.PubMedCrossRefGoogle Scholar
  5. 5.
    Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289: 1681–1690.PubMedCrossRefGoogle Scholar
  6. 6.
    Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the safety and use of statins. J Am Coll Cardiol 2002;40:568–573.CrossRefGoogle Scholar
  7. 7.
    Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. N Engl J Med 2004;292:1307–1316.Google Scholar
  8. 8.
    Bjerre LM, LeLorier J. Do statins cause cancer? Am J Med 2001;110:716–723.PubMedCrossRefGoogle Scholar
  9. 9.
    Anonymous. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005;366: 1267–1277.Google Scholar
  10. 10.
    Fish oil supplements. Med Lett 2006;48:59–60.Google Scholar
  11. 11.
    Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART). Lancet 1989;2:757–761.PubMedGoogle Scholar
  12. 12.
    Vytorin. Med Lett 2004;46:73–74.Google Scholar
  13. 13.
    Kweiterovich PO. Review of lipid modifying drugs used alone or in combination. Adv Stud Med 2005;5:475–491.Google Scholar
  14. 14.
    Telford M. Clinical pharmacokinetics of fenofibrate. Curr Med Res Opin 2003;19:139–140.PubMedCrossRefGoogle Scholar
  15. 15.
    Vega GL, Ma PT, Cater NB, et al. Effects of adding fenofibrate to simvastatin in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol 2003;91:956–960.PubMedCrossRefGoogle Scholar
  16. 16.
    Spencer GA, Wirebaugh S, Whitney EJ. Effect of a combination of gemfibrozil and niacin on lipid levels. J Clin Pharmacol 1996;36:696–700.PubMedGoogle Scholar
  17. 17.
    Brown BG, Bardsley J, Poulin D, et al. Moderate dose three-drug therapy with niacin, lovastatin and colestipol to reduce low density lipoprotein cholesterol <less than>100 mg/dL in patients. Am J Cardiol 1997;80:111–115.PubMedCrossRefGoogle Scholar
  18. 18.
    Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. 2002 ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40(3):568–573.CrossRefGoogle Scholar
  19. 19.
    CTT Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.Google Scholar
  20. 20.
    Jacobson, T. Overcoming “ageism” bias in the treatment of hypercholesterolemia: a review of safety issues with statins in the elderly. Drug Saf 2006; 29(5):421–448.PubMedCrossRefGoogle Scholar
  21. 21.
    Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005; 95:120–122.PubMedCrossRefGoogle Scholar
  22. 22.
    Insull W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006; 99(3):257–272.PubMedCrossRefGoogle Scholar
  23. 23.
    Miller M. Niacin as a component of combination therapy for dyslipidemia. Mayo Clin Proc 2003; 78:735–742.PubMedCrossRefGoogle Scholar
  24. 24.
    MICROMEDEX (2006). DRUGDEX Evaluations: Ezetimibe.Google Scholar
  25. 25.
    Bruckert E, Giral P, Tellier P. Perspectives in cholesterol-lowering therapy. The role of ezetimibe, a new selective inhibitor of intestinal cholesterol absorption. Circulation 2003;107:3124–3128.PubMedCrossRefGoogle Scholar
  26. 26.
    Saito Y, Yamada N, Teramoto T, et al. A randomized, double blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002;162:373–379.PubMedCrossRefGoogle Scholar
  27. 27.
    Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. N Engl J Med 2004;350:1505–1515.PubMedCrossRefGoogle Scholar
  28. 28.
    Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292–2300.PubMedCrossRefGoogle Scholar
  29. 29.
    Rader DJ. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003;92(4A):42 J–49 J.Google Scholar
  30. 30.
    Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581–2586.PubMedCrossRefGoogle Scholar
  31. 31.
    Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, Rimonabant, for management of obesity and related risks. Circulation 2006;114:974–984.PubMedCrossRefGoogle Scholar
  32. 32.
    Goronzy JJ, Weyand CM. Immunosuppression in atherosclerosis: mobilizing the opposition within. Circulation 2006;114:1901–1904.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Chair and Associate Professor, Department of Family MedicineUniformed Services University of the Health SciencesMD

Personalised recommendations